360 related articles for article (PubMed ID: 23146455)
1. Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients.
Kaplinsky E; González-Costello J; Manito N; Roca J; Barbosa MJ; Nebot M; Salazar-Mendiguchia J; Berdejo J; Mañas P; Miralles A; Cequier A
Transplant Proc; 2012 Nov; 44(9):2564-6. PubMed ID: 23146455
[TBL] [Abstract][Full Text] [Related]
2. Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate.
Arora S; Gude E; Sigurdardottir V; Mortensen SA; Eiskjær H; Riise G; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Aukrust P; Solbu D; Iversen M; Gullestad L
J Heart Lung Transplant; 2012 Mar; 31(3):259-65. PubMed ID: 22333403
[TBL] [Abstract][Full Text] [Related]
3. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
4. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
[TBL] [Abstract][Full Text] [Related]
5. Recovery of renal function in heart transplantation patients after conversion from a calcineurin inhibitor-based therapy to sirolimus.
Ayub-Ferreira SM; Avila MS; Feitosa FS; Souza GE; Mangini S; Marcondes-Braga FG; Issa VS; Bacal F; Chizzola PR; Cruz FD; Bocchi EA
Transplant Proc; 2010 Mar; 42(2):542-4. PubMed ID: 20304188
[TBL] [Abstract][Full Text] [Related]
6. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
Holdaas H; Rostaing L; Serón D; Cole E; Chapman J; Fellstrøm B; Strom EH; Jardine A; Midtvedt K; Machein U; Ulbricht B; Karpov A; O'Connell PJ;
Transplantation; 2011 Aug; 92(4):410-8. PubMed ID: 21697773
[TBL] [Abstract][Full Text] [Related]
7. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
[TBL] [Abstract][Full Text] [Related]
8. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
9. Conversion to everolimus in liver transplant patients with renal dysfunction.
Pérez T; Segovia R; Castro L; Roblero JP; Estela R
Transplant Proc; 2011; 43(6):2307-10. PubMed ID: 21839260
[TBL] [Abstract][Full Text] [Related]
10. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation.
Gude E; Gullestad L; Arora S; Simonsen S; Hoel I; Hartmann A; Holdaas H; Fiane AE; Geiran OR; Andreassen AK
J Heart Lung Transplant; 2010 Jun; 29(6):641-7. PubMed ID: 20304681
[TBL] [Abstract][Full Text] [Related]
11. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
[TBL] [Abstract][Full Text] [Related]
12. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
[TBL] [Abstract][Full Text] [Related]
13. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
Kushwaha SS; Khalpey Z; Frantz RP; Rodeheffer RJ; Clavell AL; Daly RC; McGregor CG; Edwards BS
J Heart Lung Transplant; 2005 Dec; 24(12):2129-36. PubMed ID: 16364861
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.
Gustafsson F; Ross HJ; Delgado MS; Bernabeo G; Delgado DH
J Heart Lung Transplant; 2007 Oct; 26(10):998-1003. PubMed ID: 17919619
[TBL] [Abstract][Full Text] [Related]
15. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
[TBL] [Abstract][Full Text] [Related]
16. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
Gullestad L; Iversen M; Mortensen SA; Eiskjaer H; Riise GC; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Gude E; Rundqvist B; Fagertun HE; Solbu D; Bergh CH
Transplantation; 2010 Apr; 89(7):864-72. PubMed ID: 20061999
[TBL] [Abstract][Full Text] [Related]
17. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.
Potter BJ; Giannetti N; Edwardes MD; Cecere R; Cantarovich M
Clin Transplant; 2007; 21(3):305-8. PubMed ID: 17488377
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects on renal function of dose-reduced calcineurin inhibitor and sirolimus in cardiac transplant patients.
Khandhar SJ; Shah HV; Shullo MA; Zomak R; Navoney M; McNamara DM; Kormos RL; Toyoda Y; Teuteberg JJ
Clin Transplant; 2012; 26(1):42-9. PubMed ID: 21303417
[TBL] [Abstract][Full Text] [Related]
19. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
[TBL] [Abstract][Full Text] [Related]
20. Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome.
Perrakis A; Schwarz K; Yedibela S; Croner RS; Hohenberger W; Müller V
Transplant Proc; 2011 Dec; 43(10):3702-7. PubMed ID: 22172830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
